Guest Editor:

Prof. Marçal Pastor-Anglada
Section of Biomedicine and Molecular Pharmacology, Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona Oncology Program, National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBER EHD) Genetics, Molecular Biology and Gene Therapy Program, Institut de Recerca Sant Joan de Déu (IR SJD)
mpastor@ub.edu

Deadline for manuscript submissions:
30 September 2017

Message from the Guest Editor

Dear Colleagues,

The International Transporter Consortium (ITC) has indicated the need to implement easy and reproducible preclinical assays suitable for the analysis of drug-transporter interactions and drug–drug interactions likely to compromise drug pharmacokinetics and pharmacodynamics. These cross-interactions have been shown, in some cases, to have a clinical impact and may be also modulated by genetic polymorphisms in the transporter-encoding genes. The two major transporter-encoding gene superfamilies in humans, SLC and ABC, include paradigms of genetic heterogeneity, although their impact on drug action and their suitability as biomarkers of individual drug-response heterogeneity have not been properly addressed thus far. The Journal of Personalized Medicine is now opening a Special Issue that is fully devoted to drug transporter functional heterogeneity, with a call for papers involving basic, translational, and clinical research on this topic.

Prof. Marçal Pastor-Anglada
Guest Editor

Author Benefits

Open Access: free for readers, with low publishing fees paid by authors or their institutions.

High visibility: citations available in PubMed; full-text archived in PubMed Central. Indexed in Scopus (from Vol. 6).

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 40 days after submission; acceptance to publication is undertaken in 9 days (median values for papers published in this journal in 2016).